Peginterferon alfa-2a (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Peginterferon alfa-2a" in English language version.

refsWebsite

Global rank English rank

7web.archive.org

1^st place

6nih.gov

4^th place

4doi.org

2^nd place

3roche.com

low place

2drugs.com

399^th place

333^rd place

2harvard.edu

18^th place

17^th place

1europa.eu

68^th place

117^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1uw.edu

low place

9,301^st place

1handle.net

102^nd place

76^th place

1epfl.ch

4,521^st place

4,877^th place

1semanticscholar.org

11^th place

8^th place

1gene.com

low place

1pharmaand.com

low place

1roche-australia.com

low place

doi.org (Global: 2^nd place; English: 2^nd place)

Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.
Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.
Rajender Reddy K, Modi MW, Pedder S (June 2002). "Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C". Advanced Drug Delivery Reviews. 54 (4): 571–86. doi:10.1016/s0169-409x(02)00028-5. PMID 12052715.
Reddy U, Krzystolik M (2006). "Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration". Cochrane Database of Systematic Reviews. 1 (1) CD005138. doi:10.1002/14651858.CD005138.pub2. PMC 12276864. PMID 16437522.

drugs.com (Global: 399^th place; English: 333^rd place)

"Peginterferon Alfa-2a (Professional Patient Advice)". drugs.com. Archived from the original on 16 January 2017. Retrieved 12 January 2017.
"Interferon alfa-2a Uses, Side Effects & Warnings". Drugs.com. Retrieved 10 January 2020.

epfl.ch (Global: 4,521^st place; English: 4,877^th place)

infoscience.epfl.ch

Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Pegasys EPAR". European Medicines Agency (EMA). 20 June 2002. Retrieved 5 September 2024.

gene.com (Global: low place; English: low place)

"Pegasys (peginterferon alfa-2a)". Genentech. Archived from the original on 8 January 2023. Retrieved 8 January 2023.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.
Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen - Summary of Product Characteristics (SPC) - (eMC)". medicines.org.uk. Archived from the original on 13 January 2017. Retrieved 12 January 2017.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.
Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.
Rajender Reddy K, Modi MW, Pedder S (June 2002). "Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C". Advanced Drug Delivery Reviews. 54 (4): 571–86. doi:10.1016/s0169-409x(02)00028-5. PMID 12052715.
Reddy U, Krzystolik M (2006). "Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration". Cochrane Database of Systematic Reviews. 1 (1) CD005138. doi:10.1002/14651858.CD005138.pub2. PMC 12276864. PMID 16437522.

ncbi.nlm.nih.gov

Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. Bibcode:2009Natur.461..798T. doi:10.1038/nature08463. PMC 3172006. PMID 19759533.
Reddy U, Krzystolik M (2006). "Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration". Cochrane Database of Systematic Reviews. 1 (1) CD005138. doi:10.1002/14651858.CD005138.pub2. PMC 12276864. PMID 16437522.

pharmaand.com (Global: low place; English: low place)

"pharma& portfolio". zr pharma& GmbH. Retrieved 4 December 2021.

roche-australia.com (Global: low place; English: low place)

"Pegasys". Roche Australia. Retrieved 8 January 2023.

roche.com (Global: low place; English: low place)

assets.cwp.roche.com

"Verzichtserklärung der Zulassung - Mittelfristig läuft Pegasys aus" (PDF) (in German). Roche. Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
"Pegasys (Peginterferon alfa-2a) langfristig weiterhin erhältlich" (PDF) (in German). Roche. Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.

roche.com

"Half-Year Report 2021, p.20" (PDF). Roche. Archived from the original (PDF) on 24 November 2021. Retrieved 4 December 2021.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. Bibcode:2009Natur.461..399G. doi:10.1038/nature08309. PMID 19684573. S2CID 1707096.

uw.edu (Global: low place; English: 9,301^st place)

hepatitisc.uw.edu

"Peginterferon alfa-2a (Pegasys) - Treatment - Hepatitis C Online". hepatitisc.uw.edu. Archived from the original on 23 December 2016. Retrieved 12 January 2017.

web.archive.org (Global: 1^st place; English: 1^st place)

"Peginterferon Alfa-2a (Professional Patient Advice)". drugs.com. Archived from the original on 16 January 2017. Retrieved 12 January 2017.
"Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen - Summary of Product Characteristics (SPC) - (eMC)". medicines.org.uk. Archived from the original on 13 January 2017. Retrieved 12 January 2017.
"Peginterferon alfa-2a (Pegasys) - Treatment - Hepatitis C Online". hepatitisc.uw.edu. Archived from the original on 23 December 2016. Retrieved 12 January 2017.
"Pegasys (peginterferon alfa-2a)". Genentech. Archived from the original on 8 January 2023. Retrieved 8 January 2023.
"Verzichtserklärung der Zulassung - Mittelfristig läuft Pegasys aus" (PDF) (in German). Roche. Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
"Pegasys (Peginterferon alfa-2a) langfristig weiterhin erhältlich" (PDF) (in German). Roche. Archived from the original (PDF) on 4 December 2021. Retrieved 4 December 2021.
"Half-Year Report 2021, p.20" (PDF). Roche. Archived from the original (PDF) on 24 November 2021. Retrieved 4 December 2021.

Peginterferon alfa-2a (English Wikipedia)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

epfl.ch (Global: 4,521st place; English: 4,877th place)

infoscience.epfl.ch

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

gene.com (Global: low place; English: low place)

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

medicines.org.uk (Global: 3,823rd place; English: 2,387th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

pharmaand.com (Global: low place; English: low place)

roche-australia.com (Global: low place; English: low place)

roche.com (Global: low place; English: low place)

assets.cwp.roche.com

roche.com

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

uw.edu (Global: low place; English: 9,301st place)

hepatitisc.uw.edu

web.archive.org (Global: 1st place; English: 1st place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 399^th place; English: 333^rd place)

epfl.ch (Global: 4,521^st place; English: 4,877^th place)

europa.eu (Global: 68^th place; English: 117^th place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

nih.gov (Global: 4^th place; English: 4^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

uw.edu (Global: low place; English: 9,301^st place)

web.archive.org (Global: 1^st place; English: 1^st place)